Regeneron has a new multiple myeloma hope
The company reveals its anti-GPRC5D T-cell engager.
J&J sidelines a novel project
The company’s TRPV1 antagonist looks doomed.
A new challenger in target degradation
Ascentage hopes to become a new force in BTK.
CCR8 promise and peril
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
AbbVie and RemeGen’s bispecific goes pivotal
Chinese trials in first-line NSCLC and colorectal cancer are imminent.
Akeso casts doubts on CD73 efforts
The company has ditched a trial of drebuxelimab plus ivonescimab.
Betta joins Revolution in pan-RAS inhibition
BPI-572270 enters clinical trials.
Like Sanofi, German Merck keeps the CEACAM5 faith
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
Ono chases Takeda in polycythemia
Ono's antisense therapy is to begin its first pivotal trial.
